When was KEDRION acquired by PERMIRA?

KEDRION was acquired by PERMIRA in 2022.

What was the revenue of KEDRION at the time of the deal?

The revenue of KEDRION at the time of the deal is estimated to be in the range of 450M - 900M EUR.

What was the EBITDA of KEDRION during the acquisition?

KEDRION's EBITDA is estimated to be in the range of 100M - 200M EUR.

How is the data for the KEDRION acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the KEDRION deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.unquote.com/unquote/official-record/3025973/permira-merges-kedrion-bpl

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaKEDRION

01/2022

KEDRION acquired by PERMIRA

ITALY Life Sciences / Pharma & Biotech / CDMO REV 450M - 900M EUR

Context

Permira acquired a controlling stake in Kedrion from the founding Marcucci family and existing institutional investors FSI and CDP Equity. The transaction was structured as a partnership where the Marcucci family, FSI, and CDP Equity reinvested a significant minority stake to maintain the group's Italian heritage and operational continuity. The deal was contingent on the simultaneous acquisition of BPL to create a unified global platform. This allowed Kedrion to secure its supply chain and significantly expand its US and international footprint while transitioning from a family-run business to a private equity-backed global player.

KEDRION, which reported an EBITDA margin of in 2020, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Kedrion is an international biopharmaceutical company that specializes in the development, production, and distribution of plasma-derived therapeutic products. It operates a vertically integrated model, from collection centers in the US to manufacturing plants in Italy, Hungary, and North America. It is a dominant player in the Italian market and the 5th largest globally in its sector.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2020

2019

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
03/2022	FRESENIUS	IVENIX	UNITED STATES	Diagnostic Equipment
02/2022	MONTAGU PRIVATE EQUITY / PARTNERS GROUP	HTL BIOTECHNOLOGY	FRANCE	CDMO
01/2022	ARDIAN	BIOFARMA GROUP	ITALY	CDMO
01/2022	PERMIRA	BIO PRODUCTS LABORATORY (BPL)	UNITED KINGDOM	CDMO
01/2022	ANJAC BEAUTY & HEALTH	APOLLO HEALTHCARE CORP.	CANADA	CDMO
12/2021	INTEGER	OSCOR	UNITED STATES	Implants & Prosthetics
12/2021	WINNCARE	PHARMAOUEST INDUSTRIES	FRANCE	Medical Devices
12/2021	THE CARLYLE GROUP / GTCR	RESONETICS	UNITED STATES	Medical Devices
12/2021	PLANMECA GROUP	KAVO DENTAL	GERMANY	Medical Devices
11/2021	COLOPLAST	ATOS MEDICAL	SWEDEN	Medical Consumables

REFERENCES

Revenue range: 450M - 900M EUR

EBITDA range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of KEDRION by PERMIRA are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: permira